Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
基本信息
- 批准号:398018062
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:德国
- 项目类别:Research Grants
- 财政年份:2018
- 资助国家:德国
- 起止时间:2017-12-31 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Our project provides a new gene and cell therapy-based strategy to treat severe combined immunodeficiency (RAG-SCID) and hyper-IgM syndrome 1 (HIGM1). Both rare primary immunodeficiencies (PIDs) manifest during the first year of life and are caused by mutations in RAG1 and CD40LG. The expression of both genes is tightly regulated. Therefore, the genetic defects cannot be treated by classical gene transfer methodology. Our strategy is based on the correction of RAG1 and CD40LG mutations by a gene-editing approach, which is followed by the adoptive transfer of gene-edited lymphoid progenitor cells (GE-LP). Both genetic defects affect B and T lymphopoiesis. They were chosen, because they can be cured by transplanting even small numbers of lymphoid progenitor cells. To correct RAG1 and CD40LG mutations in situ we will apply nuclease-mediated homologous recombination as this restores gene function while retaining the endogenous control of gene expression. Gene therapy options are also limited by the availability of hematopoietic precursor cells (HSC) from RAG-SCID and HIGM1 patients. To overcome this limitation, we will apply our gene-editing strategy human to bone marrow-derived HSC and to multipotent hematopoietic progenitors derived from induced pluripotent stem cells (iPSCs), which can be generated from many human cell types. We will validate gene-editing of RAG1 and CD40LG mutations in human HSC in vitro by measuring both functionality and molecular signatures of GE-LPs. We will then evaluate the developmental potential of GE-LPs in vivo by transplanting the cells into novel mouse strains optimized for the engraftment and multilineage differentiation of human HSC. Our project is structured into five Work Packages (WPs; Fig. 1):1) To correct disease-causing mutations by gene editing technology in situ.2) To generate GE-LPs from patient-derived iPSCs3) To generation GE-LPs from patient-derived hematopoietic stem cells4) To validate B and T cell development from GE-LPs in vitro5) To evaluate the engraftment capacity and function of GE-LPs in vivoOur combined expertise will allow the functional validation of a GE-LPs based therapy both in vitro and in vivo. Several aspects of our approach have been already adapted to GMP conditions. Together with our proven experience in translating gene therapy to the clinic, this warrants the sustained and seamless transfer of the methodology developed in this project into clinical application. We expect, that our study will provide an innovative tailored and precise gene-based treatment of PIDs.
我们的项目提供了一种新的基于基因和细胞疗法的策略来治疗严重联合免疫缺陷(RAG-SCID)和高IgM综合征1(HIGM1)。这两种罕见的原发免疫缺陷(PID)都出现在生命的第一年,都是由RAG1和CD40LG的突变引起的。这两种基因的表达都受到严格的调控。因此,遗传缺陷不能用经典的基因转移方法来治疗。我们的策略是通过基因编辑方法纠正RAG1和CD40LG突变,然后过继转移基因编辑的淋巴祖细胞(GE-LP)。这两种基因缺陷都会影响B和T淋巴细胞的生成。之所以选择它们,是因为它们可以通过移植少量的淋巴祖细胞来治愈。为了纠正RAG1和CD40LG的原位突变,我们将应用核酸酶介导的同源重组,因为这恢复了基因功能,同时保留了对基因表达的内源控制。基因治疗的选择也受到来自RAG-SCID和HIGM1患者的造血祖细胞(HSC)可用性的限制。为了克服这一限制,我们将把我们的人类基因编辑策略应用于骨髓来源的HSC和来自诱导多能干细胞(IPSCs)的多潜能造血祖细胞,IPSCs可以从许多类型的人类细胞中产生。我们将通过测量GE-LP的功能和分子特征来验证RAG1和CD40LG突变在体外对人类HSC的基因编辑。然后,我们将通过将细胞移植到新的小鼠品系中来评估GE-LPs在体内的发展潜力,这些品系优化了人类HSC的植入和多系分化。我们的项目分为五个工作包(WPS;图1):1)在特定情况下通过基因编辑技术纠正致病突变2)从患者来源的IPSC产生GE-LP到从患者来源的造血干细胞产生GE-LP 4)在体外验证从GE-LP到GE-LP的B和T细胞发育5)评估GE-LP在体内的植入能力和功能我们的联合专业知识将使基于GE-LP的治疗在体外和体内的功能验证成为可能。我们方法的几个方面已经适应了GMP的条件。再加上我们在将基因疗法转化为临床方面的成熟经验,这就保证了该项目开发的方法学能够持续和无缝地转化为临床应用。我们期待,我们的研究将提供一种创新的、量身定做的、精确的基于基因的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Professor Dr. Hermann Eibel其他文献
Professor Dr. Hermann Eibel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Professor Dr. Hermann Eibel', 18)}}的其他基金
Long-term humoral immune responses against SARS-CoV-2 in healthy individuals and patients with primary immunodeficienciess
健康个体和原发性免疫缺陷患者针对 SARS-CoV-2 的长期体液免疫反应
- 批准号:
458641632 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Research Grants
Sphingosine-1-Phosphate Receptors in Human B Cells: Expression, Role and Signaling
人类 B 细胞中的 1-磷酸鞘氨醇受体:表达、作用和信号转导
- 批准号:
39297849 - 财政年份:2007
- 资助金额:
-- - 项目类别:
Priority Programmes
Regulation of B-lymphocyte selection via transcription factors of the early growth response (Egr) gene family
通过早期生长反应 (Egr) 基因家族的转录因子调节 B 淋巴细胞选择
- 批准号:
5216756 - 财政年份:2000
- 资助金额:
-- - 项目类别:
Research Grants
相似海外基金
Efficient production of genome edited pigs from cryopreserved immature oocytes
利用冷冻保存的未成熟卵母细胞高效生产基因组编辑猪
- 批准号:
24K01915 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
A Comparative Study of The Diary of Anais Nin among the Edited, Early, Unexpurgated Edition and Archive Material
《阿奈斯·宁日记》编辑版、早期未删除版和档案资料的比较研究
- 批准号:
23K00385 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
SBIR Phase II: Clinical scale and testing of the first virus-free precision gene edited cell therapy for veterinary oncology
SBIR II 期:第一个用于兽医肿瘤学的无病毒精准基因编辑细胞疗法的临床规模和测试
- 批准号:
2243587 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Cooperative Agreement
Gene-edited liver organoids for predictive hepatotoxicity
用于预测肝毒性的基因编辑肝脏类器官
- 批准号:
10758179 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Edited Magnetic Resonance Spectroscopy of the Pediatric Brain
儿科大脑磁共振波谱编辑
- 批准号:
10583752 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Cardiac Regenerative Therapy Using Gene-Edited Stem Cells to Improve Transplantation Outcomes
使用基因编辑干细胞改善移植结果的心脏再生疗法
- 批准号:
10905166 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Mechanisms that Enhance and Suppress HIV-1 Resistance in Gene Edited Primary Human Cells
增强和抑制基因编辑原代人类细胞中 HIV-1 耐药性的机制
- 批准号:
10700726 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Study of Books for Learning the Japanese Language Edited by the Missions Etrangeres de Paris in the Early Meiji Era
明治初期巴黎侨民使团编修的日语学习书籍研究
- 批准号:
23K00547 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
FMSG: Bio: Advancing Extracellular Vesicle Biomanufacturing of CRISPR-Edited Human iPSC-derived MSCs with Next-Generation Purification
FMSG:生物:利用下一代纯化技术推进 CRISPR 编辑的人 iPSC 衍生的 MSC 的细胞外囊泡生物制造
- 批准号:
2229111 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
Risk communication for genome-edited foods to avoid making the same mistakes that were made with genetically modified foods.
基因组编辑食品的风险沟通,以避免犯与转基因食品相同的错误。
- 批准号:
23K05404 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)